Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Jim Birchenough has downgraded Sangamo Therapeutics from Overweight to Equal-Weight and set a price target of $1.
November 06, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics has been downgraded by Wells Fargo from Overweight to Equal-Weight with a price target of $1.
The downgrade from Wells Fargo could negatively impact Sangamo Therapeutics' stock price in the short term. The new price target of $1 also suggests a potential downside, which may lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100